An analysis of data from more than 1,400 patients in the U.S. found that anemia is the most reported side effect of two direct-acting antiviral drugs used to treat patients with the hepatitis C virus. Researchers found that more than 50% of the patients who took boceprevir or telaprevir experienced anemia. The findings were presented at a liver disease research meeting in Europe.

Related Summaries